Matt cofounded Audentes and has built it into a leading gene therapy company, taking it from his living room several years ago through a 2016 IPO. He has more than 20 years of experience in the research, development and commercialization of innovative treatments for rare diseases. He has been senior management at Genzyme, BioMarin and Amicus and an Entrepreneur-In-Residence with OrbiMed, Hear how Matt got there and what it’s like to operate in the hot gene therapy space in an era when we may be on the verge of curing devastating genetic disorders. Sponsored by Latham & Watkins. Tickets.